Yutaka Atomi - Sumitomo Dainippon Independent Director
| DNPUF Stock | USD 2.70 0.00 0.00% |
Director
Mr. Yutaka Atomi was serving as Independent Director of Sumitomo Dainippon Pharma Co., Ltd. since June 2017. He used to work for Kyorin University. since 2017.
| Age | 72 |
| Tenure | 7 years |
| Phone | 81 6 6203 5321 |
| Web | https://www.sumitomo-pharma.com |
Sumitomo Dainippon Management Efficiency
Sumitomo Dainippon's management efficiency ratios could be used to measure how well Sumitomo Dainippon manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 243.96 B in total debt with debt to equity ratio (D/E) of 0.36, which is about average as compared to similar companies. Sumitomo Dainippon Pharma has a current ratio of 1.71, which is within standard range for the sector. Debt can assist Sumitomo Dainippon until it has trouble settling it off, either with new capital or with free cash flow. So, Sumitomo Dainippon's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sumitomo Dainippon Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sumitomo to invest in growth at high rates of return. When we think about Sumitomo Dainippon's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | DIRECTOR Age | ||
| Zane Karimi | Knife River | N/A | |
| Alan Friedman | Cronos Group | 45 | |
| Jason Adler | Cronos Group | 46 | |
| Bronwen Evans | Cronos Group | 48 | |
| Michael Krestell | Cronos Group | N/A | |
| Ryan Roebuck | Cronos Group | 31 | |
| Kevin Crosthwaite | Cronos Group | 42 | |
| James Rudyk | Cronos Group | 51 | |
| Bruce Gates | Cronos Group | 56 | |
| Murray Garnick | Cronos Group | 58 | |
Management Performance
| Return On Equity | -0.0399 | |||
| Return On Asset | -0.0075 |
Sumitomo Dainippon Pharma Leadership Team
Elected by the shareholders, the Sumitomo Dainippon's board of directors comprises two types of representatives: Sumitomo Dainippon inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sumitomo. The board's role is to monitor Sumitomo Dainippon's management team and ensure that shareholders' interests are well served. Sumitomo Dainippon's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sumitomo Dainippon's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nobuhiko Tamura, Managing Executive Officer | ||
| Kazuo Koshiya, Executive Officer, Manager of Oncology Business Promotion Office | ||
| Saeko Arai, Independent Director | ||
| Masayo Tada, CEO and President Representative Director and Chairman of Risk Management Committee | ||
| Takuya Taguchi, Sr Unit | ||
| Hideyuki Harada, Executive Officer, Chief Director of Research | ||
| Makoto Hara, Senior Managing Executive Officer, Director | ||
| Hitoshi Odagiri, Executive Officer and Director of Personnel and Career Devel. Support | ||
| Yutaka Atomi, Independent Director | ||
| Yoshinori Ohe, Executive Officer, Director of Business Development | ||
| Kazuhiro Takada, Executive Officer, Director of Corporate Governance | ||
| Yoshihiro Okada, Managing Executive Officer, Chief Director of Production, Director | ||
| Hajime Kinuta, Executive Officer, Director of Business Planning | ||
| Susumu Nakajima, Sr. Executive Officer and Executive Director of Sales and Marketing | ||
| Hiroyuki Baba, Executive Officer | ||
| Toru Kimura, Executive Officer, Manager of Regeneration & Cell Medicine Business Promotion Office | ||
| Patricia Andrews, Executive Officer, CEO of Subsidiary | ||
| Hiroshi Sato, Independent Director | ||
| Hidehiko Sato, Independent Director | ||
| Yoshiharu Ikeda, Executive Officer, Chief Director of Technology Research | ||
| Hiroshi Noguchi, Sr. Executive VP, Executive Director of Drug Research and Representative Director | ||
| Nobuyuki Hara, Executive Officer, Chief Director of Reliability Guarantee | ||
| Naoki Noguchi, Corp Governance | ||
| Hisayoshi Kashima, Director of Accounting | ||
| Masaru Ishidahara, Sr. Executive Officer and Director | ||
| Chiang Li, Executive Officer | ||
| Mitsuyuki Taniguchi, Executive Officer, Deputy Chief Director of Sales | ||
| Hiroshi Nomura, Director | ||
| Atsuko Higuchi, Executive Officer | ||
| Shigeyuki Nishinaka, Executive Officer, Director of Business Development | ||
| Antony Loebel, Executive Officer |
Sumitomo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sumitomo Dainippon a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0399 | |||
| Return On Asset | -0.0075 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | (0.03) % | |||
| Current Valuation | 2.85 B | |||
| Shares Outstanding | 397.29 M | |||
| Shares Owned By Insiders | 58.59 % | |||
| Shares Owned By Institutions | 19.60 % | |||
| Price To Earning | 4.79 X | |||
| Price To Book | 0.64 X |
Pair Trading with Sumitomo Dainippon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sumitomo Dainippon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sumitomo Dainippon will appreciate offsetting losses from the drop in the long position's value.Moving together with Sumitomo Pink Sheet
| 0.61 | TAK | Takeda Pharmaceutical Sell-off Trend | PairCorr |
Moving against Sumitomo Pink Sheet
| 0.75 | TEVA | Teva Pharmaceutical | PairCorr |
| 0.6 | AXP | American Express Financial Report 19th of July 2024 | PairCorr |
| 0.56 | CICHF | China Construction Bank | PairCorr |
The ability to find closely correlated positions to Sumitomo Dainippon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sumitomo Dainippon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sumitomo Dainippon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sumitomo Dainippon Pharma to buy it.
The correlation of Sumitomo Dainippon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sumitomo Dainippon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sumitomo Dainippon Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sumitomo Dainippon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Sumitomo Pink Sheet analysis
When running Sumitomo Dainippon's price analysis, check to measure Sumitomo Dainippon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sumitomo Dainippon is operating at the current time. Most of Sumitomo Dainippon's value examination focuses on studying past and present price action to predict the probability of Sumitomo Dainippon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sumitomo Dainippon's price. Additionally, you may evaluate how the addition of Sumitomo Dainippon to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |